HGH 191AAvsPinealamin

Human Growth Hormone is a 191-amino-acid single-chain polypeptide secreted by somatotroph cells of the anterior pituitary gland. It exerts its effects through two distinct pathways: direct action via GH receptors and indirect action through insulin-like growth factor 1 (IGF-1). When HGH binds to the GH receptor (a type I cytokine receptor), it induces receptor dimerization and activates the JAK2/STAT5 signaling cascade, which directly stimulates gene transcription for protein synthesis, cell proliferation, and lipolysis.

The indirect pathway is equally important. GH receptor activation in hepatocytes stimulates the production and secretion of IGF-1, a 70-amino-acid peptide that circulates bound to IGF binding proteins (primarily IGFBP-3 and the acid-labile subunit). Circulating IGF-1 acts on virtually every tissue in the body — promoting amino acid uptake and protein synthesis in skeletal muscle, stimulating chondrocyte proliferation in growth plates, enhancing osteoblast activity for bone formation, and supporting neuronal survival and myelination.

GH also has profound effects on metabolism independent of IGF-1. It directly stimulates lipolysis in adipocytes by activating hormone-sensitive lipase, mobilizing stored fat as free fatty acids for energy. It antagonizes insulin action in peripheral tissues (hence the diabetogenic risk), shifting the body's fuel preference from glucose to fatty acids. In muscle, GH promotes nitrogen retention and positive protein balance. The pulsatile pattern of natural GH secretion — with the largest pulse during deep sleep — is important for its physiological effects, which is why exogenous GH protocols often try to mimic this pattern.

Pinealamin is a low-molecular-weight peptide extract derived from the pineal glands of young cattle, processed to isolate short peptides (typically under 10 kDa) with proposed bioregulatory activity on pineal gland function. Unlike defined Khavinson tripeptides such as pinealon (Glu-Asp-Arg), pinealamin is a complex mixture of multiple peptide species, and its biological activity is attributed to the combined effect of these peptides rather than a single active component.

The proposed mechanism follows the Khavinson bioregulator framework: tissue-derived short peptides preferentially target the same tissue type from which they were extracted, binding to gene promoter regions and modulating expression of genes involved in pineal-specific functions. For pinealamin, this is hypothesised to include regulation of melatonin biosynthesis enzymes (notably AANAT and HIOMT), serotonin-to-melatonin conversion pathways, and the broader hypothalamic-pituitary-pineal axis that governs circadian rhythm.

Clinical positioning is primarily for age-related decline in melatonin secretion and associated sleep disorders in older adults — Russian observational studies have reported improvements in subjective sleep quality and measured melatonin output following pinealamin courses in middle-aged and elderly subjects. As with all Khavinson cytamins, the efficacy and mechanism evidence base sits almost entirely within Russian research traditions and has not been replicated in Western randomised controlled trials. The animal-derived sourcing also raises quality and safety considerations that vary significantly between suppliers, and pharmacopoeial standards for pinealamin do not exist outside Russian regulatory frameworks.